Why the study?
Wall thickness alone is an unreliable guide to the underlying etiology of left ventricular hypertrophy, necessitating a phenotype-guided diagnostic approach to enable timely and accurate diagnosis for effective treatment.
Accurate differentiation of left ventricular hypertrophy etiologies requires a phenotype-guided multimodality imaging approach rather than relying on wall thickness alone, enabling targeted disease-modifying therapies.
Answers are grounded in this paper and cite their sources.
May reduce diagnostic delays in LVH; leaves open prospective validation of pathway accuracy and outcomes before adoption.
complemented by CMR featuring native T1 mapping and late gadolinium enhancement (LGE). 10 Targeted biochemical and radionuclide investigations (eg, serum α -galactosidase A activity, serum and urine immunofixation electrophoresis, serum-free light chains, and bone-avid tracer scintigraphy) are then deployed based on the suspected phenotype. Genetic testing and endomyocardial biopsy are reserved for cases in which noninvasive investigations remain inconclusive.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2026) conducted a review in Left Ventricular Hypertrophy (LVH). 2-step phenotype-guided clinical diagnostic pathway was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: